TWELVE-MONTH CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION TREATED WITH SACUBITRIL/VALSARTAN AT THE UNIVERSITY MEDICAL CENTER, HO CHI MINH CITY
Main Article Content
Abstract
Background: Sacubitril/valsartan improves outcomes in heart failure with reduced ejection fraction (HFrEF) in randomized trials. Real-world data from Vietnam remains limited.
Objectives: To evaluate 12-month clinical outcomes of HFrEF patients treated with and without sacubitril/valsartan in routine practice.
Methods: An ambispective cohort study of 113 HFrEF patients followed for 12 months. The primary endpoint was a composite of all-cause mortality or heart failure rehospitalization. Survival analyses were performed using Kaplan–Meier and Cox regression models.
Results: Mean age was 65.0 ± 15.3 years; baseline EF was 28.8 ± 7.7%; 60.2% were NYHA class III. At 12 months, all-cause mortality was 9.7%, rehospitalization rate 25.7%, and composite endpoint 28.3%. In unadjusted analysis, ARNI was associated with lower mortality (HR 0.13; p=0.006). After adjustment for age and baseline eGFR, ARNI remained associated with reduced mortality risk (HR 0.21; 95% CI 0.055–0.793; p=0.021). However, the association with the composite endpoint was not significant after adjustment for age and baseline eGFR (HR 0.95; p=0.913). EF improved significantly in both groups. Adverse events were comparable.
Conclusions: In this observational study, sacubitril/valsartan was associated with lower 12-month mortality in HFrEF patients, while no significant association was observed for the composite outcome after adjustment.
Article Details
Keywords
heart failure with reduced ejection fraction, sacubitril/valsartan, ARNI, mortality, rehospitalization.
References
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368.
3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure. Circulation. 2022;145(18):e895–e1032. doi:10.1161/CIR.0000000000001063.
4. Nguyễn HT, Lê HQ, Trần TML, Nguyễn VBH. Bước đầu đánh giá hiệu quả và an toàn của Sacubitril/Valsartan ở các bệnh nhân suy tim có phân suất tống máu giảm. Tạp chí Y học Thành phố Hồ Chí Minh. 2019;23(3):169-173.
5. Nguyễn NK, Nguyễn TD. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và đánh giá kết quả điều trị suy tim phân suất tống máu giảm bằng thuốc sacubitril/valsartan. Tạp chí Y Dược học Cần Thơ. 2023;(61):29-35. doi: 10.58490/ctump.2023i61.1232
6. Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. PROVE-HF Investigators. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322(11):1085–1095. doi:10.1001/jama.2019.12821.
7. Zile MR, Claggett BL, Prescott MF, McMurray JJV, Packer M, Rouleau JL, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68(22):2425–2436. doi:10.1016/jacc.2016.09.931.
8. Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial. Circ Heart Fail. 2018;11(4):e004745. doi:10.1161/Circheartfailure.117.004745.